Ozempic and his imitators

We read in the ARA that the pharmaceutical company that makes Ozempic, this weight-loss drug named after a Barça full-back, was the most valuable a few months ago, but is now making losses. It's funny that, to justify the slimming down of the squad (and pardon the verb), the directors say this: "Our markets are evolving, especially the obesity market, since it has become more competitive." In other words, obesity is "a market." A business. And, therefore, it's better for it to last.

I suppose that those who buy Ozempic—aside from diabetics, for whom it was intended—are people who are incapable, for whatever reason, of doing what you should do when you're overweight because of eating and drinking too much, which is to eat and drink less and better and exercise. Here where we live, we overeat because we buy excess food all the time. We don't cook, we buy it ready-made, just peel off the plastic and eat it in a snap (perhaps standing up, without any ceremony). If we happen to boil broccoli ("how boring, boiled broccoli, why don't we go to the Japanese?") we take advantage of the time to watch videos on Instagram, we don't even realize what we're doing, which is preparing food.

This pharmaceutical company, of course, has suffered the same fate as the coffee capsule company. It is seeing imitators. (By the way, you could make monthly meals, balanced and fresh, for an entire family and there would be enough left over to go to a restaurant to enjoy), but they already say that in a few years "it could be produced in India for just over $4 a month", because, where we suffer from the problem of being overweight, we will be buying malnutrition.